Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...

Coral is growing in Albany. There's a place that sells coral on Colvin Avenue, but that's just a small part of what they do. There's also a lot of drug research and reef restoration work.

With Gaza Takeover Plan, an Unbound Trump Pushes an Improbable Idea Once a critic of nation building, President Trump now envisions taking over a Middle East enclave, driving out its Palestinian ...

Forecast issued at 4:30 pm WST on Monday 3 February 2025.

The show is coming to a planned end and was not canceled despite other reports.